https://scholars.lib.ntu.edu.tw/handle/123456789/635776
標題: | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | 作者: | Cho, Byoung Chul Ahn, Myung-Ju Kang, Jin Hyoung Soo, Ross A Reungwetwattana, Thanyanan CHIH-HSIN YANG Cicin, Irfan Kim, Dong-Wan Wu, Yi-Long Lu, Shun Lee, Ki Hyeong Pang, Yong-Kek Zimina, Anastasia Fong, Chin Heng Poddubskaya, Elena Sezer, Ahmet How, Soon Hin Danchaivijitr, Pongwut Kim, YuKyung Lim, Yeji An, Taewon Lee, Hana Byun, Hae Mi Zaric, Bojan |
公開日期: | 10-九月-2023 | 卷: | 41 | 期: | 26 | 來源出版物: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 摘要: | Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/635776 | ISSN: | 0732-183X 1527-7755 |
DOI: | 10.1200/JCO.23.00515 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。